Shingles vaccine demand rises amid potential dementia prevention links

Demand for the shingles vaccine is increasing significantly across pharmacies in Britain, with major chains like Boots and Superdrug reporting substantial rises in bookings. While the vaccine is primarily designed to prevent the painful shingles rash caused by the reactivation of the varicella zoster virus, a growing number of people are seeking it due to research suggesting a potential link to reduced dementia risk.

Scientific studies have observed associations between shingles vaccination and lower dementia rates. A Stanford University analysis of data from Wales suggested that vaccine-eligible women had dementia rates 8.5% lower over seven years, with some estimates suggesting a potential risk reduction of nearly 20%. An Oxford University study of over 200,000 individuals found that those receiving the Shingrix vaccine had 17% fewer dementia cases compared to those who received Zostavax, with women showing a 22% reduction compared to 13% for men.

Researchers theorize that the virus, which remains dormant in nerve cells after chickenpox, may drive brain inflammation and the accumulation of amyloid and tau proteins associated with Alzheimer’s disease. However, experts emphasize that these findings indicate correlation and association rather than definitive proof of causation, and the vaccine is not currently approved for dementia prevention.